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Abstract 
Although the study of the association between interventions in primary care and health outcomes continues to 
produce mixed findings, programs designed to promote the greater compliance of General Practitioners and 
their diabetic patients with treatment guidelines have been increasingly introduced worldwide, in an attempt 
to achieve better quality diabetes care through the enhanced standardisation of patient supervision. In this study 
we use clinical data taken from the Diabetes Register of one Local Health Authority (LHAs) in Italy’s Emilia-
Romagna Region for the period 2014-2015. Firstly, we test to see whether the monitoring activities prescribed 
for diabetics by regional diabetes guidelines, actually have a positive impact on patients’ health outcomes and 
increase appropriateness in health care utilization. Secondly, we investigate whether GPs’ participation in the 
local Diabetes Management Program (DMP) leads to improved patient compliance with regional guidelines. 
Our results show that such a program, which aims to increase GPs’ involvement and cooperation in following 
regional guidelines for best practices, achieves its goal of improved patient compliance with the prescribed 
actions. In turn, through the implementation of the DMP and the greater involvement of physicians, regional 
policies have succeeded in promoting better health outcomes and the improved appropriateness of health care 
utilization. 
Keywords: diabetes care, clinical guidelines, primary care, Diabetes Management Programs. 
JEL codes: C21, I10, I18, H51 
                                                     
1 The project is the result of a partnership entitled “Economic evaluation of clinical pathways and prescribing 
appropriateness” between the School of Health Policies-University of Bologna and the Regional Agency for 
Health and Social Care of the Emilia-Romagna Region (ASSR-RER), with the cooperation of the Local Health 
Authority of Parma. The three institutions have jointly concurred to the project with their own resources with 
the ASSR-RER assuring the financial resources necessary for research assistant contracts. The ASSR-RER 
and the Local Health Authority of Bologna provided the databases used in this study. The opinions expressed 
here are the sole responsibility of the authors and do not represent the views of the ASSR-RER. The usual 
disclaimers apply. 
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NON-TECHNICAL SUMMARY 
 
Long-run demographic and epidemiological trends have brought the treatment of chronic diseases to the 
forefront of the health policy agenda, with diabetes raising widespread concern due to its high prevalence 
among the elderly. Nowadays, diabetes management relies strongly on risk-reduction strategies, most of which 
are based on routine monitoring mainly based on periodic tests for haemoglobin A1c, lipid and 
microalbuminuria determination. The study of the association between patient surveillance and health 
outcomes has produced mixed findings, in particular for chronic patients affected by multiple morbidities. 
Despite that, the enhanced standardisation of patient supervision based on a designated set of activities is 
believed to improve the quality of diabetes care.  
A large number of initiatives for disease management have been launched with the purpose of reducing 
heterogeneity in clinical decision making, and of aligning physician’s behaviour with evidence-based best 
practices. They typically reward GPs for their involvement in cooperative activities, the compliance of their 
treatment methods to best practices, or their achievement of specific targets. In this paper, we address two key 
issues for the success of Diabetes Management Programs (DMPs). First, we examine the association between 
health outcomes and routine patient screening. When drafting DMPs, the benefits from regular monitoring are 
often posited in advance, whereas their ex-post measurement is a fundamental step to support the content of 
the guidelines. Hence, as a first step in our analysis, we test whether diabetics who enjoy regular monitoring 
in primary care, display better health outcomes regardless of whether they are enrolled in a structured program. 
The second goal of the paper is to study whether patients enrolled in a DMP have a higher probability of 
successfully meeting the guidelines’ requirements. By doing so, we can establish the effectiveness of DMP as 
a policy tool for promoting compliance with best practices and thereby improving patient health. We use data 
from Bologna, the largest Local Health Authority (LHAs) within Italy’s Emilia-Romagna Region, covering 
the period 2014-2015, consisting in a combination of patient and GP-level data taken from administrative 
sources and from the Diabetes Register containing clinical information.  
The estimates show that, compared to patients who fail to follow the prescriptions, those who enjoy regular 
monitoring display better health outcomes. Moreover, we found that participation in the DMP program 
increases the probability of adherence to the surveillance standards established by the guidelines. Overall, such 
evidence supports the effectiveness of the disease-management program in promoting regular patient 
supervision, since enrolment in the program favours the likelihood of compliance with best practices, and, in 
turn, such actions are associated to beneficial effects on health. From a policy perspective, identifying an 
institutional arrangement like the DMP that encourages observance of diabetes guidelines, has implications 
for the design of policies that may be extended to other chronic conditions as well. 
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1. Introduction 
Long-run demographic and epidemiological trends have brought the treatment of chronic diseases to the 
forefront of the health policy agenda, with diabetes raising widespread concern due to its high prevalence, 
especially among the elderly. Nowadays, diabetes management relies strongly on risk-reduction strategies, 
most of which are based on routine monitoring [WHO, 2016]. As unstructured care is often associated with 
greater mortality and other adverse outcomes, Diabetes Management Programs (DMPs) are deemed to reduce 
short- and long-term complications [Wagner et al. 2001]. Based on the consensus view that periodic tests for 
haemoglobin A1c, lipid and microalbuminuria determination and eye examination favour the timely 
identification and effective treatment of patients, clinical guidelines for best practices recommend the regular 
screening of diabetics [International Diabetes Federation 2017; De Micheli, 2008]. The study of the association 
between patient surveillance and health outcomes has produced mixed findings, in particular for chronic 
patients affected by multiple morbidities. Despite that, the enhanced standardisation of patient supervision 
based on a designated set of activities is believed to improve the quality of diabetes care [Tricco et al., 2012; 
Smith et al 2016; Simcoe, Catillon and Gertler, 2018].  
A large number of initiatives for disease management have been launched with the purpose of reducing 
heterogeneity in clinical decision making, and of aligning physician’s behaviour with evidence-based best 
practices. They typically reward GPs for their involvement in cooperative activities, the compliance of their 
treatment methods to best practices, or their achievement of specific targets. Despite this, compliance with the 
prescribed behaviour remains unsatisfactory in many cases [Oh et al. 2016; Kirkman et al., 2001; Beaulieu et 
al. 2006]. GPs’ reluctance to comply with top-down directives is mainly attributed to the time and effort 
required to implement guidelines. However, it also results in some cases from GPs’ opposition to audits and 
other monitoring schemes limiting their self-determination, together with scepticism in regard to the idea that 
standardised behaviour is always the best response to patients’ needs [Zwolsman et al., 2012; Cook et al., 
2018]. 
In this paper, we address two key issues for the success of Diabetes Management Programs (DMPs). First, we 
examine the association between health outcomes and routine patient screening. When drafting DMPs, the 
benefits from regular monitoring are often posited in advance, whereas their ex-post measurement is a 
fundamental step to support the content of the guidelines. Hence, as a first step in our analysis, we pursue this 
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aim by testing whether diabetics who enjoy regular monitoring in primary care, display better health outcomes 
regardless of whether they are enrolled in a structured program. The second goal of the paper is to study 
whether patients enrolled in a DMP have a higher probability of successfully meeting the guidelines’ 
requirements. By doing so, we can establish the effectiveness of DMP as a policy tool for promoting 
compliance with best practices and thereby improving patient health.  
Our study contributes to an increasingly rich economic literature on the role of primary care policies in treating 
chronic conditions, and diabetes in particular (e.g. Gil, Sicras-Mainar, Zucchelli 2018, Andrade, Rapp, Sevilla-
Dedieu 2018, Iezzi, Lippi Bruni, Ugolini 2014, Dusheiko et al. 2011). We use data from the largest Local 
Health Authority (LHAs) within Italy’s Emilia-Romagna Region, covering the period 2014-2015, consisting 
in a combination of patient and GP-level data taken from administrative sources and from the Diabetes Register 
containing clinical information. We show first that the successful completion of a cycle of screening activities 
during the course of the previous year, significantly improves patient outcomes as measured by a reduction in 
the probability of the onset of new diabetic complications (Odds Ratio-OR 0.882), of all-cause hospitalisations 
(OR 0.832) and of hospitalisations for Ambulatory Care Sensitive Conditions-ACSCs (OR 0.826); while no 
significant effect is found in terms of avoidable emergency admissions. We then show that enrolled patients 
display a significantly higher rate of compliance with monitoring prescriptions, and a probability of 
compliance that is nearly four (two and half) times as large as that of non-enrolled ones, depending on whether 
more (less) restrictive criteria for adherence are considered. From a policy perspective, identifying an 
institutional arrangement like the DMP that encourages observance of diabetes guidelines, has implications 
for the design of policies that may be extended to other chronic conditions as well. 
The remainder of the paper is organised as follows: in the next section we discuss the related literature, while 
section 3 presents the institutional background; in section 4, we describe the data and the empirical strategy; 
our empirical findings are discussed in section 5; and finally, section 6 offers some conclusions. 
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2. Background literature 
Diabetes management programs consist of multifaceted interventions aimed at promoting better quality 
standards through effective incentive schemes [Scott and Farrar, 2003; Sutton et al., 2010; Iversen and Luras, 
2012]. This notwithstanding, the study of their impact often produces non-conclusive findings. The best-
known European example is the UK’s Quality and Outcomes Framework (QOF), which rewards high quality 
in primary care and promotes standardised medical practices. Sutton et al. (2011) find that this program has 
had positive effects, concluding that financial incentives have induced providers to increase targeted quality; 
while Kontopantelis et al. (2013) confirm the quality improvement (measured by achievement of the 17 
diabetes process and outcome indicators from the QOF) after the introduction of the program specifically 
aimed at diabetes care. On the other hand, however, Roland and Guthrie (2016) point out that the QOF-related 
gains in quality, including those pertaining to diabetes, were in line with similar improvements recorded over 
the same period for conditions left out of the program. This signals the difficulty of isolating the effects of the 
program from those effects produced by general improvements in medical practice. 
An important feature of these initiatives concerns their underlying incentives. Factors such as the broadness of 
the targets, the involvement of providers in drafting the program, and the rules for assigning the rewards, may 
all contribute towards successfully reorienting physicians’ behaviour [Eijkenaar, 2013]. Proponents of the use 
of payments that are conditional on the achievement of pre-established health outcomes, have stressed their 
potential for enhancing the quality of care, whereas critics have raised doubts over their effectiveness. In this 
vein, and in keeping with a long line of research in psychology, the economic literature has highlighted the 
potential of flawed incentive schemes to undermine or “crowd out” intrinsic motivation [Promberger and 
Marteau, 2013; Irlenbusch and Sliwka, 2005; Gneezy et al., 2011]. When paying-for-performance curbs 
intrinsic motivation to perform the task for its own sake, physicians’ responses may fail to meet the policy 
goals set by the health authority. If financial incentives belittle the non-financial motivations of providers (e.g. 
altruism), they could be harmful, especially in National Health Systems (NHS) where the public mission is 
expected to favour physicians’ compliance with the system’s societal objectives [Siciliani, 2009]. Conversely, 
low-powered incentives not directly linked to patient outcomes, can induce crowding-in effects, facilitate 
cooperation, and further the alignment of the objectives of clinicians with those of policy makers [Fiorentini 
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et al. 2011]. For example, the payment of a fixed additional amount per chronic patient included in the managed 
care programme, may help increase treatment adherence, reduce patient selection, enforce cooperation and 
preserve intrinsic motivations. Whether these factors ultimately improve patients’ outcomes, even if they are 
not explicitly targeted, remains an empirical matter. The existing literature has pointed out that there are 
circumstances in which low-powered incentives based on process measures may have a significant impact on 
the quality of care [Dumont et al., 2008]. One example in the case of diabetes is provided by the experiences 
developed in Canada and Australia where physicians are rewarded for complying with guidelines when treating 
diabetes patients [Kantarevic and Kralj, 2013; Scott et al., 2009; Comino et al., 2013].  
As regards Italy, earlier analyses have examined the impact of DMPs within the same institutional context 
considered in the present paper, where payments for diabetes-related initiatives are not contingent on health 
outcomes. Rather, they link financial reward to the GP’s assumption of responsibility for diabetic patients. By 
exploiting heterogeneity in program implementation across practices, prior studies have shown that even if the 
achievement of health outcomes is not directly rewarded, DMPs reduce the probability of hyperglycaemic 
emergencies and hospital admissions for ACSCs in diabetics [Lippi Bruni et al., 2009, Iezzi et al., 2014].  
One limitation of the contributions referred to above is that they rely exclusively on administrative data. By 
contrast, in this study we use richer, more recent sources of information consisting in a combination of 
administrative data with data reporting individual values for diabetes-related biomarkers. This enables us to 
control for diabetes severity at individual level, as the Register contains information on the HbA1c values 
recorded at each visit. A further advantage of the Diabetes Register is that it permits identification of those 
patients enrolled in the protocol for integrated diabetes care within each GP’s list. Thanks to this additional 
information, we can exploit patient-level data in order to assess whether fulfilling monitoring standards has 
beneficial effects on health indicators that are not specifically rewarded by the program, and at the same time, 
whether participation in DMPs based on low-powered incentives increases compliance with clinical 
guidelines. Our findings are consistent with the view that promoting GPs’ assumption of responsibility for 
diabetic patients, increases their involvement in the treatment of chronic diseases. In this way the policy 
reduces the probability of adverse events, and likely contributes towards slowing the deterioration in health 
generally associated with diabetes [Parsons et al., 2010]. 
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3. The institutional framework 
The Italian National Health Care System (NHS) is a decentralised public health service, mainly funded 
through general taxation, where regions autonomously manage and deliver health services via Local Health 
Authorities (LHAs). Each LHA is organised into Local Health Districts (LHDs) that provide community 
and hospital services and coordinate primary care activities. Each patient is registered with a GP, who is a 
self-employed professional contracted to the NHS, mainly paid on a capitation basis under a contract 
negotiated between the central government and primary care organisations. Moreover, Regional Governments 
can introduce additional remuneration for selected activities, which results in substantial variability across the 
country. 
In 2003, the Emilia-Romagna Department of Health issued its “Clinical Guidelines for Management of 
Diabetes Mellitus” prescribing the following actions: (1) the measurement of Hb1Ac twice a year; (2) blood 
cholesterol and urinary micro albumin tests once a year; (3) an electrocardiogram and/or visit to a cardiologist 
every 1-2 years; (4) ophthalmologic monitoring by means of an ocular fundus examination every 1-2 years. 
The same document introduces a new organizational model based on integrated care management with a 
multidisciplinary team and the proactive approach to type-2 diabetes patients at LHA level through a Diabetes 
Management Program called “Integrated Management” (IM) involving GPs, nurses and other healthcare 
professionals [Emilia-Romagna Region, 2003, 2009]. Patients can be enrolled in the IM program if they do 
not exceed a given severity threshold (i.e. they are without complications or with minor complications, 
otherwise they have to be managed by the Diabetic Centre. Conditions to qualify for IM enrolment are: stable 
metabolic compensation and a limited number of mild complications (in particular no medium and severe 
micro-macro vascular complications). GPs are expected to play an active role in the management of enrolled 
patients, by planning access to the practice according to the IM protocol. Based on local agreements between 
the LHA and GPs, each district applies the criteria so as to reward GPs for performing those activities required 
by the regional guidelines. This is generally performed by setting a fixed additional fee per enrolled patient for 
whom the designated cycle of activities has been successfully completed.  
In this study we benefit from information retrieved from the Administrative Databases and the Diabetes 
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Register of the Local Health Authority of Bologna that serves a population of almost 1 million inhabitants. 
GPs enrolled into the IM protocol receive an additional fixed payment that increases capitation for each 
diabetic patient taking part in the program; this payment is designed to remunerate the GP for the additional 
time and effort required to manage such patients.  
 
4. Methods 
4.1 The Data 
Our primary data cover the year 2015. The study, based on routine administrative information and on the 
diabetes clinical register, was carried out in conformity with the regulations on data management of the Emilia-
Romagna Region and with Italian privacy law. Administrative data were linked to the diabetes registers’ data 
and anonymised by an ad hoc service located in the Regional Health Directorate. The Health and Social 
Regional Agency and the University of Bologna have no possibility to retrospectively identify individuals 
included. When informed consent cannot be obtained, the Italian law requires ethical approval for retrospective 
studies for non-anonymous data only, hence such approval was not required given the completely anonymous 
nature of the data.  
The baseline population for the present study comprises residents living within the Bologna LHA catchment 
area. The population within this area amounts to nearly 1 million people and represents almost one fourth of 
the Emilia-Romagna Region’s total population. Moreover, Bologna LHA enjoys a prominent role in the 
regional health care system as a result of its technologically advanced hospital system and its well-established, 
comprehensive organisation of community care services. Data taken from the Regional Healthcare 
Information System are used to identify our study population, which consists of all residents over the age of 
18 years who have received at least two diabetes drug prescriptions (oral agents or insulin) over the previous 
three years (2012-14). As this criterion fails to detect patients treated through diet and exercise, following the 
criteria established by the Regional Department of Health, we also include outpatients who attended a Diabetes 
Centre over the previous three years, together with inpatients diagnosed with diabetes.  
Thanks to the records linking administrative and clinical datasets, we merge patient characteristics and 
information on pharmaceutical treatment, together with diabetes-related biomarkers and information about the 
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organisational setting for diabetes management. Three mutually exclusive organisational arrangements can be 
identified: that of low-severity patients enrolled in the IM program under the responsibility of their own GP; 
that of low-severity patients followed by a GP who does not enrol in the IM program; and that of medium or 
high-severity patients treated by the Diabetic Centre. As the paper focuses on the role of IM managed by GPs, 
we exclude from the estimating sample those individuals managed exclusively by Diabetes Centres, as they 
are complex patients for whom the responsibility for compliance rests on the Diabetes Centre rather than on 
the GP. Finally, in order to unambiguously assign the information on GP characteristics to each patient, we 
keep in our cohort only those diabetics who remained with the same GP over the entire year 2015. This led to 
the exclusion of 368 patients (1.2% of the initial sample). The resulting dataset includes 30,577 patients 
registered with 700 GPs located in 6 LHDs. 
Table 1a presents the dependent variables employed in the analysis. We distinguish between dichotomous 
indicators of the quality of diabetes care shown in the upper panel of the table, and of adherence to guidelines 
shown in the lower panel of the table. The former set of variables is used in the first stage of our analysis, 
while the latter set is used in the second stage.  
As measures for quality, we use the onset of new diabetes-related complications arising in 2015, together with 
indicators of the utilisation of hospital services, which are commonly used as indicators for poor surveillance 
in primary care. Given that effective disease management should avoid complications and rapid health 
deterioration, these measures were chosen based on medical evidence showing that the high-quality treatment 
of diabetes is associated with fewer hospital admissions. We focus first on admissions for ACSCs, conditions 
that should be prevented through timely monitoring and effective treatment in an ambulatory care setting 
[Billings et al., 1993, Caminal et al. 2004]. Alternatively, we consider all-cause hospitalisations, since non-
adherence may reduce the effectiveness of treatment, making patients more vulnerable and exposed to the need 
for hospital assistance [Andrade, Rapp, Sevilla-Dedieu, 2018]. Finally, we include indicators for avoidable 
emergency visits [Lippi Bruni, Mammi, Ugolini, 2016]. In sum, the quality of diabetes care is measured using 
four dichotomous variables. For the year 2015, we consider patients who: (1) had at least one new diabetes-
related complication; (2) were hospitalised for at least one ACSC; (3) had at least one inappropriate access to 
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the Emergency Department, based on the Italian four-level triage system (white codes); (4) were hospitalised 
at least once for any cause. 
Table 1a shows the descriptive statistics for the quality indicators considered. All-cause hospitalisation 
involves nearly one fifth of the diabetics (18.8%), followed by patients for whom at least one new complication 
was recorded in 2015 (6.4%), and by those who experienced at least one avoidable admission to the ED (5.5%). 
Only 2.7% of diabetes patients were hospitalised for ACSCs in 2015. To give a sense of the degree of 
association among these dichotomous health outcomes, Table 1b shows conditional probabilities for pairwise 
associations between health outcomes. The data shows that 93.95% of patients with at least one new 
complication in 2015 were also hospitalised for any cause, 19.6% for an ACSC and only 9.53% were admitted 
to the ED for a non-urgent episode. A high degree of association is recorded also for patients with at least one 
ACSC hospitalisation, nearly half of whom experienced a new complication in 2015. In all other cases, the 
degree of association ranges from 4% to 30%, suggesting that the set of outcomes covers a fairly broad range 
of conditions, capturing different kinds of failure in patient supervision.  
We measure adherence to guidelines using two indicators: the first indicator is a dummy identifying patients 
who performed at least two HbA1c during 2015, which is the most important recommendation included in the 
guidelines. The second indicator is based on the more restrictive criterion requiring controls for blood 
cholesterol and urinary micro albumin in addition to the two HbA1c tests. When assessing patient compliance, 
we do not consider the other recommendations included in the official guidelines for different reasons. 
Electrocardiogram and ophthalmologic monitoring are not required on an annual basis, thus raising problems 
in properly identifying cases of non-compliance given the short timespan covered by our data. In addition, 
patients frequently receive ocular fundus examination privately during an ophthalmologic visit and 
consequently the total number of eye examinations is largely underestimated in the NHS administrative 
dataset, as this only records treatment provided by the public sector. 
In our sample, the overall share of patients meeting the first compliance criterion is around one-third (34%). 
The share is 45.48% in the case of patients enrolled in an IM program, and 25.50% for those not enrolled in 
such. Diabetics undergoing two HbA1c tests and one microalbuminuria screening account for approximately 
11 
 
one quarter of the total (26%), with shares of 39.26% for patients enrolled in an IM program, and of 15.79% 
for non-enrolled ones (Table 1a).   
INSERT TABLE 1A AND TABLE 1B 
Table 2 provides the descriptive statistics for the covariates of our estimating sample. Patients’ characteristics 
include gender, age, foreign citizenship, regular insulin use, the presence of at least one chronic disease, the 
adherence to clinical guidelines in the previous year (e.g. two HbA1c tests plus one blood cholesterol and one 
urinary micro albumin screening during 2014), enrolment in the Integrated Management program. In addition, 
given that glycaemic control is a key factor in reducing the risk of complications, we exploit the measure of 
blood glucose in the previous year to classify patients into three categories on the basis of the reported HbA1C 
value. To be classified as compensated, patients must report glycated haemoglobin levels of less than 7% 
before the age of 60, below 7.5% when aged between 60 and 75, and below 8% when aged 75 or more. 
Conversely, patients are classified as decompensated if they display values that exceed the above thresholds. 
Finally, patients are classified as partially compensated if they present values both above and below the critical 
thresholds within the same year. 
53% of our cohort are males, the average age of patients is 70, and 76% of them have at least one chronic 
disease. Foreigners account for 5% of the total, while 7% of the sample received at least one insulin 
prescription in 2015, and nearly three-quarters have compensated diabetes (73%). Almost 42% of those in the 
sample are enrolled in the IM program.  
GPs’ characteristics include age and gender, practice type (individual practices are distinguished from group 
practices), together with a set of dummies for list size and share of diabetic patients in the list. About 65% of 
GPs are male, and their average age is 60, 77% of them work in a group practice, and an average 3% of their 
registered patients are diabetics. To account for unobserved heterogeneity at the local level, we include 
dummies for the six districts of the Bologna LHA in all our estimates. 
INSERT TABLE 2 
4.2 Empirical strategy 
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In the light of the hierarchical structure of the data at hand, where patients are nested within GPs, we base our 
estimation strategy on multilevel regression models which consider the joint influence of characteristics 
measured at different levels. Clustered data of this kind are characterized by multilevel dependency, and by 
possible correlation among units, that must be accounted for since the independence assumption of the error 
terms is challenged by patients being nested into practices. Because of this, standard regression techniques can 
produce downward biased standard errors, whereas a multilevel regression approach overcomes this problem 
by assessing variability at each layer separately [O’Connell et al., 2008; Goldstein, 2010]. 
A two-level generalized linear multilevel model can be written as follow: 
𝜋𝑖𝑗 = 𝑓(𝑋𝛽)𝑖𝑗       [1] 
where 𝜋𝑖𝑗 is the expected value of the response variable for the i-th patient and j-th GP, X is a vector of the 
independent variables, is the associated vector of parameters, and f is a non-linear link function of the linear 
predictor (𝑋𝛽)𝑖𝑗. Due to the dichotomous nature of all outcomes, we specify a Bernoulli distribution for the 
dependent variables and a logit link function. Therefore, the general model can be written as follows: 
𝑙𝑜𝑔𝑖𝑡 (𝜋𝑖𝑗) = (𝑋𝛽)𝑖𝑗 + 𝑣𝑗 + 𝜀𝑖𝑗        [2] 
where 𝑣𝑗 ∼ 𝑁(0, 𝜎𝑣
2)  is a Gaussian-distributed random effect term specific for the j-th GP, and 𝜀𝑖𝑗 ∼ 𝑁(0, 𝜎𝜀
2) 
is a gaussian-distributed error term specific for the i-th patient and the j-th GP. 
Following O’Connell et al. (2008), we estimate an unconditional model (i.e. with no covariates) and compute 
the intraclass correlation coefficient (ICC) in order to evaluate the basic partitioning of the variability of the 
outcomes at GP level. Larger values of ICC (0<ICC<1) are indicative of greater potential for each layer to 
influence the dependent variable. 
𝐼𝐶𝐶 =
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝐺𝑃𝑠
𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒
           [3] 
We then perform regression analyses by estimating multilevel models for each dependent variable, and control 
for the set of explanatory variables previously presented. Multilevel modelling estimation is based on 
maximum likelihood procedure using Laplace approximation. Statistical analysis was performed using the 
SAS/STAT 9.4 software PROC GLIMMIX procedure, at a 95% confidence level. Statistical significance was 
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evaluated by means of the Wald test statistic, and goodness-of-fit was assessed using deviance [-2Ln(L)] 
[Goldstein, 2010].  
Our empirical strategy is organised in two distinct steps, both based on the estimate of multilevel logit models 
as described in equation [2]. They include up to two levels, the first referring to the patient, the second to the 
GP’s practice. Together with the estimated coefficients and p-values, we also compute the odds ratios (OR) in 
order to quantify the impact of each covariate on the outcomes of interest. 
First, we test whether compliance with regional guidelines in the previous year has a positive impact on the 
quality of care, as measured by an array of dichotomous dependent variables that capture designed to account 
for poor patient supervision and low-quality care. The use of multiple outcomes is meant to accommodate the 
multidimensional nature of health, by covering a broad spectrum of potential effects. As already illustrated, 
our outcomes are dichotomous variables that take value 1 for the following: diabetics with a new diabetes-
related complication; diabetics hospitalized for an ACSC; diabetics who have been hospitalised once; diabetics 
who have had at least one inappropriate access to the ED, respectively. We model each dummy indicator 
separately as depending upon a set of controls for patient and practice characteristics. The covariate we are 
mainly interested in is the dichotomous indicator of compliance with clinical guidelines during the previous 
year. We consider compliance with best practices to be satisfied if patients performed at least two HbA1c, 
blood cholesterol and microalbuminuria tests in 2014. This covariate allowed us to assess the impact of prior 
treatment adherence on health outcomes in diabetes patients. All other controls refer to the year 2015, but the 
degree of diabetes compensation is evaluated based on information for the year 2014. 
Having established whether regular routine examinations are associated with better outcomes, irrespective of 
the patient’s participation in a DMP, our second goal is to assess whether enrolment in a DMP increases 
compliance with the activities designated by the guidelines. We test if patients enrolled in an IM program are 
more likely to perform the prescribed tests than are patients not part of such a program. To account for different 
degrees of compliance, we consider patients who undertook at least two Hb1Ac tests per year in the first place. 
We then also established a more restrictive criterion whereby, in addition to blood glucose control, compliant 
patients are also required to have one blood cholesterol test and one urinary micro albumin test. 
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The compliance indicators are regressed against the same set of covariates from the previous specification, 
augmented by a dummy for patient enrolment in the IM program representing the variable of main policy 
interest in this case. This allows us to test whether patients participating in a structured DMP based on 
Integrated Management protocols, are more likely to comply with regional guidelines than non-enrolled 
patients are.  
 
5. Results 
Table 3 reports the estimates for the variance components and for the ICC from the empty models. Such 
estimates of health outcomes are not always significant, suggesting that the hierarchical nature of the data 
affects the variability of our health indicators to a limited extent only. On the contrary, we get larger estimates 
for the ICC when we consider adherence to guidelines as a dependent variable. Using the compliance criterion 
based on blood glucose tests only, the intra-group correlation is equal to 13% at GP level, whereas including 
one cholesterolemia and one microalbuminuria in addition to the two HbA1C tests per year, the ICC for the 
GP layer increases to 18%. In these latter cases, the share of variability explained by the GP layer supports the 
choice of multilevel specification. 
INSERT TABLE 3 
Table 4 presents the estimates of the multilevel logit model discussed in Equation [2], where the dependent 
variables are the health indicators, and we focus on the impact of compliance with best practices during the 
previous year. Coefficients, standard errors, p-values and odds ratios are reported for each specification.  
As for the covariate of main policy interest, we find a significant and negative association between adherence 
to the guidelines in the previous year and the probability of suffering a new diabetes-related complication, an 
ACSC and an all-cause hospitalisation; whereas no significant effect on inappropriate ED admissions was 
found. The difference in the odds between compliers with guidelines and non-compliers is of a similar 
magnitude for both measures of hospital admissions (ACSCs and all-cause hospitalisations), while a relatively 
smaller effect was found in terms of the probability of new complications. The estimated impact indicates that 
non-compliers have 20% greater odds than compliers do when the adverse outcome is measured in terms of 
either type of hospital admission, and 13% greater odds in terms of new complications. Overall, these empirical 
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findings support the adoption of patient monitoring strategies based on the prescriptions set out in regional 
guidelines, as they seem to help slow down the onset of new complications and to prevent the unnecessary use 
of hospital services.  
As expected, patients’ characteristics emerge as good predictors of the probability of adverse health outcomes, 
although there is some heterogeneity across indicators. In particular, three out of the four outcomes are 
significant and positively correlated with patient age. The only exception is inappropriate ED admissions, 
which occur more frequently among younger patients. Rather than better health conditions, the latter result 
likely reflects a lower propensity to classify ED admissions by elderly patients as inappropriate due to such 
patients’ high vulnerability and exposure to complications. Female patients are significantly less likely to 
experience diabetes-related complications or to be hospitalized, whereas no significant gender difference is 
detected for ED admissions. Interestingly, natives display a higher probability of all-cause hospitalisations, 
but a lower probability of being inappropriately accessing hospital services in the form of either ED access or 
an ACSC admission. The smaller probability of hospitalisation in general in the case of foreigners is consistent 
with the healthy immigrant hypothesis (Moullan and Jusot, 2014). As for ED visits, the result is in line with 
prior evidence showing that in Italy, as in many other countries, foreigners display a relatively higher 
propensity to use emergency services than natives do (De Luca et al. 2013). The most interesting policy 
indication emerges from the different propensity to inappropriate hospital admissions of natives and foreigners. 
Since our data do not record the contacts between patients and GPs, at this stage we cannot establish whether 
the aforesaid result is due to a lower propensity to attend primary care practices, or to other problems in the 
patient-physician relationship (e.g. communication) that weakens disease prevention among foreigners. Still, 
as long as foreigner status is a significant predictor of the avoidable use of hospital services, this helps identify 
an area of intervention with regard to primary care, and highlights the need for targeted initiatives in favour of 
foreign diabetic patients.  
As expected, severity indicators such as insulin dependence or the presence of other chronic conditions are 
positively correlated with new complications and the extra-utilisation of health care services. These factors are 
by large those leading to the greatest increase in the probability of adverse outcomes. For both severity 
measures, the odds-ratios range from 3.7 to 4.5 in the case of new complications and ACSC admissions, and 
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from 1.2 to 3.2 in the case of all-cause hospitalisations and avoidable ED admissions. Compensated diabetes 
in 2014 does not affect the probability of experiencing a new complication in the following year. On the 
contrary, compensated patients are more likely to be hospitalised, which is in keeping with recent findings in 
Spain [Gil, Li Donni, Zucchelli, 2018]. Most controls included at GP level do not affect the observed outcomes.  
INSERT TABLE 4 
Table 5 presents the estimates of the multilevel logit model described in Equation [2] using the two indicators 
of adherence to guidelines as dependent variables. Our empirical evidence shows that enrolment in an IM 
program leads to a significant increase in compliance with clinical guidelines, which suggests that patients 
with similar degree of diabetes severity, and treated by GPs with similar characteristics, are more likely to 
undergo regular blood glucose control and microalbuminuria tests when they are enrolled in the IM program. 
The odds ratio for enrolled patients is more than twice as large (OR 2.5) than for non-enrolled diabetics in the 
specification accounting for HbA1C tests only, and almost four times larger (OR 3.9) when microalbuminuria 
is also considered. The main policy implication is that participation in a Diabetes Management Program that 
includes a structured clinical pathway identifying precise requirements for regular patient monitoring, proves 
effective in improving patient compliance.  
In this case, the role of patients’ characteristics appears relatively less important than in the previous case, in 
terms of both the significance of the coefficients and of the magnitude of the estimated effects. We find no 
significant difference in compliance across genders, and age also plays a minor role. Significant differences in 
compliance are found between natives and foreigners, with native patients showing greater compliance with 
clinical guidelines than foreign patients do. Not surprisingly, insulin users and patients with other chronic 
diseases are more likely to comply with the routine tests (OR 1,3). These findings suggest that the more severe 
the patient’s condition, the more effective are the GP’s recommendations to follow the guidelines, because of 
the high exposure to possible complications. Practice level controls do not affect the observed outcomes, with 
the exception of being assisted by a female GP, which significantly increases the probability of guideline 
compliance.  
INSERT TABLE 5 
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6. Conclusion  
The design of disease management programs capable of improving the quality of outpatient care, is a 
challenging and highly debated policy issue; this is due to the widespread belief that when properly 
incentivised and implemented, such initiatives can lead to better health outcomes and can curb the unnecessary 
use of the health services. This topic is especially important in the case of chronic diseases, among which 
diabetes plays a prominent role. Despite the worldwide introduction of programs relying on guidelines for best 
practices, the evidence concerning the impact of actions promoting better diabetes surveillance remains 
inconclusive. Moreover, as the initiatives differ in a number of ways, empirical studies should try to account 
for the distinguishing features of the different experiences concerned. Therefore, new insights into the extent 
to which these programs improve health outcomes, and into the role of their specific characteristics are 
extremely helpful to policymakers wishing to improve the design of such schemes.  
We have focused on DMPs, where targets refer to process measures based on the regular monitoring of 
patients, and not to health outcomes. The rationale behind such an approach is twofold: the prescribed actions 
are ultimately expected to have beneficial effects on patients’ health; enrolment into the program is expected 
to steer the adoption of the recommended behaviour. Given this background, we tested the two hypotheses 
separately, thus providing a comprehensive assessment of the impact of the program. Using data from the 
Bologna Local Health Authority, we first investigated whether regular supervision of diabetic patients is 
associated with better health outcomes and with a reduced utilisation of hospital services. Secondly, we studied 
the effect that enrolment in a formal program has on the probability of meeting the guideline-recommended 
prescriptions requiring the regular testing of diabetes patients on a yearly basis.  
Starting from a reference population of around 1,000,000 inhabitants, we extracted a cohort of around 30,000 
diabetic patients using the criteria set by the Regional Department of Health. Given the purposes of the study, 
our estimating sample comprises patients with mildly and medium severe diabetes, since more complex cases 
come under the responsibility of the Diabetes Centre and not of the GP, and so are not eligible for the program. 
The cross-sectional data used for the analysis refer to the year 2015, and they contain both patient- and GP-
level information, merging administrative and clinical sources, including a biomarker for glucose 
concentration (HbA1C level).  
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Our empirical strategy is organised in two separate steps, both of which are based on the estimate of multilevel 
logit models. In the first step, alternative indicators for health and hospital utilisation are regressed against 
patients’ and GPs’ characteristics. In the second step, the dependent variable is defined on the basis of various 
compliance criteria, and the same set of regressors was augmented by the inclusion of a variable accounting 
for individual enrolment in the program. 
The estimates show that, compared to patients who fail to follow the prescriptions, those who enjoy regular 
monitoring display better health outcomes in terms of the lesser likelihood of new complications, and of more 
limited utilisation of hospital services (all-cause hospitalisations and ACSCs). On the contrary, no significant 
difference was recorded for avoidable ED admissions. Moreover, we found that participation in the IM 
program increases the probability of adherence to the surveillance standards established by the guidelines. 
Overall, such evidence supports the effectiveness of the disease-management program in promoting regular 
patient supervision, since enrolment in the program favours the likelihood of compliance with best practices, 
and, in turn, such actions are associated to beneficial effects on health. The results have therefore important 
implications also for health care financing, since, by containing the utilisation of health services, improved 
patient supervision seems to have the potential of reducing the economic burden of disease that for diabetes 
has been proven to be large (e.g. Mata-Cases et al. 2016, Baudot et al. 2019).  
Nevertheless, the study also suffers from certain limitations that cannot be overlooked. In particular, the 
geographical and time dimensions of the data are not ideal, and as such they limit the extent of our conclusions. 
As with the first issue, our findings are restricted to a single LHA, and the possibility of extending the analysis 
to regional (or even national) level would reinforce its external validity. Secondly, and more importantly, the 
cross-sectional nature of the data does not allow to control for unobserved patient heterogeneity. Because of 
this, our findings, linking routine tests to health outcomes (first step) and DMP enrolment to treatment 
adherence (second step), should to be interpreted as statistical associations rather than causal relationships.  
Despite these drawbacks, the internal consistency of the empirical evidence and its robustness across multiple 
health and compliance indicators, still deliver valuable policy insights into the role of disease management 
programs for the treatment of chronic conditions. Moreover, the analysis furthers our understanding of types 
of programs that have been little explored in the literature, as they rely on low-powered incentives. This is the 
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case of payments contingent on the GP’s assumption of responsibility for the diabetic patient, through 
counselling and regular monitoring, rather than on the achievement of specific health outcomes.  
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Table 1A. Outcome variables 
Dependent variable  Number of cases % 
Quality of care    
At least one new diabetes-related complications 1,954 6.39 
At least 1 ACSC 828 2.71 
At least 1 inappropriate ED access  1,675 5.47 
At least 1 hospitalisation 5,754 18.82 
   
Adherence to guidelines    
At least 2 Hb1Ac 10,350 33.85 
At least 2 Hb1Ac, 1 cholesterolemia and 1 microalbuminuria 7,828 25.60 
All variables are dummy indicators. Shares are computed using the total number of patients as denominator (N= 30,577). All data refers to year 2015.  
 
 
 
Table 1B.  Association between outcome variables,  
 At least 1 new 
diabetes- related 
complication 
At least 1 
ACSC 
At least 1 
hospitalisation 
At least 1 
inappropriate ED 
access 
Totals 
At least 1 new diabetes- related 
complication 
1953 
(100%) 
383 
(19.61%) 
138 
(92.93%) 
169 
(9.53%) 
1953 
(100%) 
At least 1 ACSC 383 
(46.20%) 
829 
(100%) 
829 
(100%) 
68 
(8.89%) 
829 
(100%) 
At least 1 hospitalisation 1815 
(31.56%) 
829 
(14.41%) 
5751 
(100%) 
472 
(8.92%) 
5751 
(100%) 
At least 1 inappropriate ER access 169 
(10.60%) 
68 
(4.27%) 
472 
(29.61%) 
1594 
(100%) 
1594 
(100%) 
Each cell displays the number of patients jointly experiencing the row and column outcome. The probability of the column outcome conditional on 
the row outcome is reported in parenthesis. Year 2015. 
 
 
Table 2. Control variables 
Explanatory variable Coding  Values 
Patient Level (n=30577)    
Patient Female Female=1 % 47.07 
Patient age Years Mean 70.11 
Patient Native Native=1 % 94.88 
Insulin user User=1 % 6.86 
Chronic Disease At least one=1 % 85.91 
Adherence to guidelines 2014 Yes=1 % 33.71 
IM (Integrated management) IM=1 % 41.80 
Compensated diabetes 
Decompensated diabetes 
Partially compensated diabetes 
Compensated 
Decompensated 
Partially compensated 
% 
72.88 
17,90 
9.22 
GP Level (n=700)    
GP gender Female=1 % 35.02 
GP age  Years Mean 59.91 
GP list size 
Low (<800) 
Medium (800-1500) 
High (>1500) 
% 
% 
% 
7.14 
44.86 
48.00 
Diabetic patients in list  Percentage Mean 3.44 
Associated Practice  Associated=1 % 77.29 
Patient and GP characteristics, year 2015. All variables expressed as shares except for Patient age and GP age expressed in years.  
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Table 3. Variance components of models 
 At least 1 complication  At least 1 ACSC 
 Coef S.E. p-value  Coef S.E. p-value 
Level 2-  𝝈𝟐(𝒗𝒌) 0.024 0.019 0.101  0.018 0.045 0.347 
Level 2-ICC 0.007    0.005   
-2ln(L) 14518.99  7615.77 
 At least 1 hospitalisation  At least 1 inappropriate ER access 
 Coef S.E. p-value  Coef S.E. p-value 
Level 2- 𝝈𝟐(𝒗𝒌) 0.012 0.008 0.065  0.119 0.029 <.0001 
Level 2-ICC 0.004    0.035   
-2ln(L) 29552.71  12338.30 
 At least 2 HB1Ac  
At least 2 Hb1Ac, 1 cholesterolemia and 1 
microalbuminuria 
 Coef S.E. p-value  Coef S.E. p-value 
Level 2-  𝝈𝟐(𝒗𝒌) 0.488 0.037 <.0001  0.717 0.054 <.0001 
Level 2-ICC 0.129    0.179   
-2ln(L) 35575.10  32248.84 
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Table 4. Health outcomes 
 New complications ACSCs All-cause hospitalisation Avoidable ED access 
 Coef S.E. p-value OR Coef S.E. p-value OR Coef S.E. p-value OR Coef S.E. p-value OR 
Intercept -4.209 -4.209 0.504  -6.508 0.7695 <.0001  -2.0468 0.3101 <.0001  -1.1823 0.5152 0.0221  
Patient level 
Patient Age 
 
0.041 0.003 <.0001 1.041 0.072 0.005 <.0001 1.075 0.017 0.002 <.0001 1.017 -0.008 0.003 0.004 0.992 
Patient Female 
 
-0.531 0.059 <.0001 0.588 -0.159 0.089 0.075 0.853 -0.130 0.036 0.000 0.878 0.063 0.061 0.305 1.065 
Patient Native 
 
-0.242 0.174 0.163 0.785 -0.634 0.279 0.023 0.531 0.203 0.108 0.060 1.225 -0.470 0.128 0.000 0.625 
Insulin user 
 
1.401 0.080 <.0001 4.058 1.384 0.119 <.0001 3.989 1.171 0.061 <.0001 3.226 0.272 0.113 0.016 1.313 
Compensated Diabetes 
 
-0.100 0.081 0.219 0.905 -0.130 0.129 0.312 0.878 0.187 0.054 0.001 1.205 0.133 0.088 0.128 1.142 
Partially compensated 
Diabetes 
0.070 0.113 0.536 1.072 0.083 0.177 0.640 1.086 0.378 0.075 <.0001 1.460 -0.058 0.131 0.658 0.943 
Chronic Disease 
 
1.324 0.171 <.0001 3.757 1.507 0.340 <.0001 4.515 0.744 0.075 <.0001 2.104 0.253 0.104 0.015 1.287 
Guidelines 2014 
 
-0.126 0.061 0.038 0.882 -0.191 0.096 0.046 0.826 -0.184 0.038 <.0001 0.832 0.048 0.064 0.456 1.049 
GP level 
Age GP 
 
0.003 0.007 0.627 1.003 -0.015 0.010 0.133 0.985 0.000 0.004 0.993 1.000 -0.004 0.007 0.600 0.996 
Female GP 
 
-0.012 0.067 0.863 0.989 -0.051 0.101 0.613 0.950 0.054 0.041 0.185 1.056 0.008 0.071 0.907 1.008 
Associated Practice  
 
0.016 0.087 0.859 1.016 -0.1331 0.128 0.300 0.875 0.036 0.054 0.506 1.037 0.056 0.092 0.546 1.057 
% Diabetics in list 
 
1.867 2.540 0.463 6.466 1.5381 3.694 0.020 4.656 0.578 1.578 0.714 1.782 -2.604 2.724 0.339 0.074 
Small GP List  
 
0.144 0.192 0.454 1.155 0.113 0.280 0.687 1.119 0.015 0.128 0.906 1.015 0.365 0.191 0.055 1.441 
Medium GP List  
 
-0.013 0.065 0.844 0.987 -0.123 0.099 0.2167 0.884 0.054 0.040 0.180 1.055 0.017 0.071 0.815 1.017 
Districts Yes Yes Yes Yes 
Variance components 
Level 2- 0.028 0.027 0.159  0.003 0.066 0.482  0.007 0.010 0.247  0.049 0.033 0.071  
Level 2-ICC 0.008    0.001    0.002    0.015    
2ln(L) 
9631.3
7 
    4635.10   20000.17    8895.09    
All specification based on multilevel logit models (GP and patient layer).  Coefficients, standard errors, p-values and odd-ratios reported for each specification.  Year 2015.
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Table 5. Adherence to guidelines 
 At least 2 Hb1Ac 
At least 2 Hb1Ac, 1 cholesterolemia and 1 
microalbuminuria 
 Coef S.E. p-value OR Coef S.E. p-value OR 
Intercept -0.306 0.4955 0.5372  -0.492 0.5879 0.4031  
Patient level 
Patient Age 
 
-0.001 0.001 0.357 0.999 -0.008 0.001 <.0001 0.992 
Patient Female 
 
0.039 0.031 0.204 1.040 -0.058 0.033 0.081 0.944 
Patient Native 
 
0.273 0.080 0.001 1.313 0.284 0.087 0.001 1.328 
Insulin user 
 
0.634 0.060 <.0001 1.885 0.601 0.064 <.0001 1.82 
Compensated Diabetes 
 
0.001 0.044 0.988 1.001 -0.134 0.047 0.005 0.875 
Partially compensated 
Diabetes 
 
0.689 0.062 <.0001 1.992 0.466 0.065 <.0001 1.593 
Chronic Disease 
 
0.345 0.051 <.0001 1.412 0.309 0.056 <.0001 1.361 
Integrated Management 
(IM) 
 
0.913 0.036 <.0001 2.493 1.352 0.040 <.0001 3.864 
GP level 
Age GP 
 
-0.004 0.008 0.588 0.996 -0.005 0.009 0.563 0.995 
Female GP 
 
0.215 0.075 0.004 1.240 0.238 0.089 0.008 1.269 
Associated Practice  
 
-0.042 0.093 0.654 0.959 -0.056 0.111 0.616 0.946 
% Diabetics in list 
 
-1.519 2.904 0.601 0.219 2.060 3.457 0.551 7.844 
Small GP List  
 
-0.011 0.174 0.948 0.989 0.228 0.203 0.262 1.255 
Medium GP List  
 
-0.042 0.073 0.566 0.959 -0.081 0.087 0.349 0.922 
Districts YES YES 
Variance components 
Level 2- 0.493 0.040 <.0001  0.723 0.058 <.0001  
Level 2-ICC 0.130    0.180    
2ln(L) 25736.91    22518.80    
All specification based on multilevel logit models (GP and patient layer).  Coefficients, standard errors, p-values and odd-ratios reported for each 
specification.  Year 2015. 
 
 
